| Description: |
Julia Frimmel,1 Anke Morgner,2 Claudia Brogsitter,3 Karolin Trautmann-Grill,4 Desiree Kunadt,4 Raphael Teipel,4 Christoph Röllig,4 Mathias Hänel,2 Johannes Schetelig,4,5 Friedrich Stölzel,1,6 Martin Bornhäuser4,7,8 1Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Internal Medicine II, University Hospital Schleswig Holstein, University Kiel, Kiel, Germany; 2Department for Internal Medicine II, Klinikum Chemnitz, Chemnitz, Germany; 3Department of Nuclear Medicine, University Hospital Dresden, University Dresden, Dresden, Germany; 4Department of Internal Medicine I, University Hospital Dresden, University Dresden, Dresden, Germany; 5DKMS Clinical Trials Unit, Dresden, Germany; 6Faculty of Medicine Dresden, University Dresden, Dresden, Germany; 7German Cancer Consortium (DKTK) Partner Site Dresden, Dresden, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; 8National Center for Tumor Diseases (NCT) Dresden, Dresden, GermanyCorrespondence: Julia Frimmel, Rosalind-Franklin-Straße 12, Kiel, 24105, Germany, Email Julia.Frimmel@uksh.dePurpose: Although emerging therapies for multiple myeloma (MM) have improved treatment options, long-term disease control in relapsed/refractory (r/r) MM remains a challenge. While the effect of natural killer cell alloreactivity in haploidentical allogeneic hematopoietic cell transplantation (HCT) with post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GvHD) prophylaxis is considered a standard treatment option for several hematologic neoplasms, its use in MM is controversial. In this retrospective analysis, we evaluated a small cohort of consecutive patients with MM who underwent haploidentical allogeneic HCT with PTCy.Patients and Methods: With a median follow-up of 68 months (range, 2– 109 months), seven consecutive patients with r/r MM underwent haploidentical HCT. All were heavily pre-treated, having received proteasome inhibitors, anti-CD38 antibody, immunomodulatory drugs, and at least one autologous ... |